(CercleFinance.com) – Jefferies maintains its Buy recommendation on Biogen stock and its price target at $240.
“The FDA briefing materials for Friday’s AdCom of Leqembi are relatively positive,” begins the analyst who anticipates an upvote regarding his clinical benefit.
“We expect straight-forward approval and no major labeling issues,” the broker says.
The launch will take time in the second half of the year, but Jefferies expects it to ramp up in 2024,’ as medical centers build infusion capacity and the like. ‘.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes disseminated by Cercle Finance only constitute a decision-making aid for investors. The responsibility of Cercle Finance cannot be held directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional adviser before any investment. This indicative information does not in any way constitute an incitement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends with the buttons below.
